A Phase 1 interventional study of Selexipag (adult formulation) and Selexipag (pediatric formulation) in Healthy Subjects, sponsored by Actelion. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Clinical study in healthy adult subjects to compare the adult tablet of selexipag with the tablet developed for children.
Healthy male adults receive a single dose of selexipag (200 µg) but using a different tablet strength (4 film-coated pediatric tablets of 50 µg versus one film-coated tablet of 200 µg selexipag) during each of the two study periods. There is a washout of 7-9 days between the two study treatment administrations.
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Key inclusion Criteria:
Key exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
Drug: Selexipag (adult formulation) · Drug: Selexipag (pediatric formulation)
Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
Drug: Selexipag (adult formulation) · Drug: Selexipag (pediatric formulation)
One selexipag film-coated tablet of 200 µg
Also known as: ACT-293987
Four selexipag film-coated tablets of 50 µg
Also known as: ACT-293987
Area under plasma concentration-time curve [AUC(0-inf)] of selexipag and ACT-333679
AUC(0-inf) is the area under plasma concentration-time curves for selexipag and its metabolite (ACT-333679), calculated from zero to the extrapolated infinite time
Time frame: From predose until 72 hours postdose for each treatment period
Maximum plasma concentration (Cmax) of selexipag and ACT-333679
Cmax is directly derived from the individual plasma concentration time curves for selexipag and its metabolite ACT-333679
Time frame: From predose until 72 hours postdose for each treatment period
Time to reach Cmax (tmax) of selexipag and ACT-333679
tmax is directly derived from the individual plasma concentration time curves for selexipag and its metabolite ACT-333679
Time frame: From predose until 72 hours postdose for each treatment period
Terminal half-life (t½) of selexipag and ACT-333679
The period of time required for the concentration levels of selexipag or its metabolite (ACT-333679) to be reduced by one-half
Time frame: From predose until 72 hours postdose for each treatment period
Area under plasma concentration-time curve [AUC(0-t)] of selexipag and ACT-333679
AUC(0-t) is the area under plasma concentration-time curves for selexipag and its metabolite (ACT-333679), calculated from zero to time t of the last measured concentration above the limit of quantification
Time frame: From predose until 72 hours postdose for each treatment period
Incidence of treatment-emergent adverse events and serious adverse events
A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment, including any abnormalities in ECG parameters, vital signs or laboratory tests
Time frame: From first administration of selexipag (Day 1 Period 1) to end of study (Day 4, Period 2)
Incidence of safety events of interest
Events of interest include any abnormalities in ECG, vital signs or laboratory test results
Time frame: From first administration of selexipag (Day 1 Period 1) to end of study (Day 4, Period 2)
No study locations are listed for this record.
Plan to share: No
The record gives a start of Jun 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag